Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas
暂无分享,去创建一个
K. Papadopoulos | S. Kroll | T. Lampidis | L. Raez | C. Rocha-Lima | A. Ricart | J. Rosenblatt | K. Tolba | V. Langmuir | M. Brawer